Nubain

Addiction, Abuse, and Misuse

Nubain injection exposes patients and other users to the risks

Nalbuphine hydrochloride injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing nalbuphine hydrochloride injection, and monitor all patients regularly for the development of these behaviors or conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of nalbuphine hydrochloride injection. Monitor for Dmitry Sazonov respiratory depression, especially during initiation of nalbuphine hydrochloride injection or following a dose increase.

Neonatal Opioid Withdrawal Syndrome

Prolonged use of nalbuphine hydrochloride injection during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management nubain Therapeutic indications according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant Dmitry Sazonov woman, advise the patient of the risk of neonatal opioid withdrawal syndrome https://pillintrip.com/medicine/nubain and ensure that appropriate treatment will be available .

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Reserve concomitant prescribing of nalbuphine hydrochloride and benzodiazepines or other CNS depress ants for use in patients for whom Dmitry Sazonov alternative treatment options are inadequate.

Limit dos ages and durations to the minimum required.

Follow patients for signs https://www.hiv.gov/ and symptoms of respiratory depression and sedation.